Literature DB >> 8068872

Hepatorenal syndrome: emerging perspectives of pathophysiology and therapy.

M Epstein.   

Abstract

Progressive oliguric renal failure (designated "hepatorenal syndrome") commonly complicates the course of patients with advanced hepatic disease. Despite the severe derangement of renal function and ominous prognosis when renal failure develops, minimal and inconsistent pathologic abnormalities of the kidneys are found at autopsy. Furthermore, the kidneys, if transplanted, are capable of normal function, which supports the concept that the renal failure is functional and potentially reversible. In contrast to patients with classical acute failure (ATN), hepatorenal syndrome patients manifest characteristic alterations of renal function including (1) relatively hyperosmolar urine; (2) high creatinine urine:plasma ratio, and (3) a very low urine sodium concentration (< 10 mEq/L). The past several years have witnessed newer insights into both the pathophysiology and the therapeutics of this syndrome. The application of newer methodology such as tracer kinetics has more rigorously delineated the role of a number of pathogenic mechanisms including activation of the sympathetic nervous system. The characterization of endothelin and the nitric oxide-arginine pathway and their roles in biology and medicine has provided additional new insights with regard to the pathogenesis of hepatorenal syndrome. For example, nitric oxide has been proposed to constitute a mediator of both the hyperdynamic circulation and renal failure. Finally, recently initiated therapeutic approaches lend a note of optimism to the future management of a syndrome that is so often incompatible with recovery. These include the acceptance of orthotopic liver transplantation as definitive treatment for patients with end-stage liver disease and attempts to improve renal function by countervailing the decreases in systemic vascular resistance while minimizing concomitant increments in renal vascular resistance. Hopefully, ongoing and future clinical trials will establish the precise contribution of each of these treatment modalities and their respective roles in the therapeutic armamentarium.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8068872     DOI: 10.1681/ASN.V4101735

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  10 in total

Review 1.  Renal autoregulation: new perspectives regarding the protective and regulatory roles of the underlying mechanisms.

Authors:  Rodger Loutzenhiser; Karen Griffin; Geoffrey Williamson; Anil Bidani
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2006-05       Impact factor: 3.619

Review 2.  New Developments in Hepatorenal Syndrome.

Authors:  Ayse L Mindikoglu; Stephen C Pappas
Journal:  Clin Gastroenterol Hepatol       Date:  2017-06-07       Impact factor: 11.382

3.  Elevated carboxy terminal cross linked telopeptide of type I collagen in alcoholic cirrhosis: relation to liver and kidney function and bone metabolism.

Authors:  S Møller; M Hansen; J Hillingso; J E Jensen; J H Henriksen
Journal:  Gut       Date:  1999-03       Impact factor: 23.059

4.  Acute hepatic ischemic-reperfusion injury induces a renal cortical "stress response," renal "cytoresistance," and an endotoxin hyperresponsive state.

Authors:  Richard A Zager; Ali C M Johnson; Kirsten B Frostad
Journal:  Am J Physiol Renal Physiol       Date:  2014-07-30

5.  Prediction of outcome in patients with liver dysfunction after left ventricular assist device implantation.

Authors:  Hiroyuki Nishi; Koichi Toda; Shigeru Miyagawa; Yasushi Yoshikawa; Satsuki Fukushima; Daisuke Yoshioka; Tetsuya Saito; Shunsuke Saito; Taichi Sakaguchi; Takayoshi Ueno; Toru Kuratani; Yoshiki Sawa
Journal:  J Artif Organs       Date:  2013-08-29       Impact factor: 1.731

Review 6.  Hepatorenal Syndrome: Physiology, Diagnosis and Management.

Authors:  Joseph Chmielewski; Robert J Lewandowski; Haripriya Maddur
Journal:  Semin Intervent Radiol       Date:  2018-08-06       Impact factor: 1.513

7.  A pilot study to evaluate renal hemodynamics in cirrhosis by simultaneous glomerular filtration rate, renal plasma flow, renal resistive indices and biomarkers measurements.

Authors:  Ayse L Mindikoglu; Thomas C Dowling; Jade J Wong-You-Cheong; Robert H Christenson; Laurence S Magder; William R Hutson; Stephen L Seliger; Matthew R Weir
Journal:  Am J Nephrol       Date:  2014-06-17       Impact factor: 3.754

8.  Effects of urodilatin on natriuresis in cirrhosis patients with sodium retention.

Authors:  Jan Carstens; Henning Grønbaek; Helle K Larsen; Erling B Pedersen; Hendrik Vilstrup
Journal:  BMC Gastroenterol       Date:  2007-01-26       Impact factor: 3.067

9.  Hepatic vein pressure predicts GFR in cirrhotic patients with hemodynamic kidney dysfunction.

Authors:  Neel Desai; Joel Neugarten; Mary Dominguez; Ladan Golestaneh
Journal:  Physiol Rep       Date:  2017-06

Review 10.  Calponin control of cerebrovascular reactivity: therapeutic implications in brain trauma.

Authors:  Christian W Kreipke; Jose A Rafols
Journal:  J Cell Mol Med       Date:  2009-02       Impact factor: 5.310

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.